This company is no longer active
CRXT.Q Stock Overview
Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Clarus Therapeutics Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0011 |
| 52 Week High | US$3.94 |
| 52 Week Low | US$0.001 |
| Beta | 0 |
| 11 Month Change | -92.81% |
| 3 Month Change | -94.63% |
| 1 Year Change | -99.92% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.99% |
Recent News & Updates
Shareholder Returns
| CRXT.Q | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 0.1% | 0.6% |
| 1Y | -99.9% | 18.8% | 30.3% |
Return vs Industry: CRXT.Q underperformed the US Pharmaceuticals industry which returned 6% over the past year.
Return vs Market: CRXT.Q underperformed the US Market which returned -10.9% over the past year.
Price Volatility
| CRXT.Q volatility | |
|---|---|
| CRXT.Q Average Weekly Movement | 47.7% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CRXT.Q's share price has been volatile over the past 3 months.
Volatility Over Time: CRXT.Q's weekly volatility has increased from 35% to 48% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 16 | n/a | clarustherapeutics.com |
Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill’s proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans.
Clarus Therapeutics Holdings, Inc. Fundamentals Summary
| CRXT.Q fundamental statistics | |
|---|---|
| Market cap | US$57.22k |
| Earnings (TTM) | -US$24.49m |
| Revenue (TTM) | US$16.91m |
0.0x
P/S Ratio0.0x
P/E RatioIs CRXT.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRXT.Q income statement (TTM) | |
|---|---|
| Revenue | US$16.91m |
| Cost of Revenue | US$3.62m |
| Gross Profit | US$13.29m |
| Other Expenses | US$37.77m |
| Earnings | -US$24.49m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 78.58% |
| Net Profit Margin | -144.82% |
| Debt/Equity Ratio | -310.1% |
How did CRXT.Q perform over the long term?
See historical performance and comparison